Arcellx (ACLX) Stock Price, News & Analysis

Company Overview

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Key Stats

• Today's Range: $67.36 to $70.24
• 50-Day Range: $62.93 to $95.72
• 52-Week Range: $47.88 to $107.37
• Volume: 822,149 shs
• Average Volume: 638,399 shs
• Market Capitalization: $3.68 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $105.93
• Consensus Rating: Buy

Arcellx Stock Analysis - MarketRank™

Arcellx scored higher than 59% of companies evaluated by MarketBeat, and ranked 496th out of 957 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Arcellx has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 13 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Arcellx has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Arcellx are expected to decrease in the coming year, from ($1.58) to ($2.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arcellx is -95.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arcellx is -95.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arcellx has a P/B Ratio of 6.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.46% of the float of Arcellx has been sold short.

Short Interest Ratio / Days to Cover

Arcellx has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Arcellx has recently increased by 15.32%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arcellx does not currently pay a dividend.

Dividend Growth

Arcellx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.46% of the float of Arcellx has been sold short.

Short Interest Ratio / Days to Cover

Arcellx has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Arcellx has recently increased by 15.32%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.51

News Sentiment

Arcellx has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Arcellx this week, compared to 5 articles on an average week.

Search Interest

3 people have searched for ACLX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

6 people have added Arcellx to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Arcellx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,242,800.00 in company stock.

Percentage Held by Insiders

Only 6.24% of the stock of Arcellx is held by insiders.

Percentage Held by Institutions

96.03% of the stock of Arcellx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ACLX Stock Analysis - Frequently Asked Questions

How have ACLX shares performed this year?

Arcellx's stock was trading at $76.69 at the start of the year. Since then, ACLX shares have decreased by 11.2% and is now trading at $68.13.
View the best growth stocks for 2025 here.

How were Arcellx's earnings last quarter?

Arcellx, Inc. (NASDAQ:ACLX) released its earnings results on Thursday, November, 7th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.06. The company had revenue of $26.03 million for the quarter, compared to analyst estimates of $35.21 million. Arcellx had a negative trailing twelve-month return on equity of 8.28% and a negative net margin of 25.94%.

When did Arcellx IPO?

Arcellx (ACLX) raised $132 million in an initial public offering on Friday, February 4th 2022. The company issued 8,250,000 shares at $15.00-$17.00 per share.

Who are Arcellx's major shareholders?

Top institutional shareholders of Arcellx include Rhumbline Advisers (0.11%), Congress Asset Management Co. (0.05%), State of New Jersey Common Pension Fund D (0.04%) and Harbor Capital Advisors Inc. (0.04%). Insiders that own company stock include Enterprise Associates 15 New, Sr One Capital Management, Llc, Jill Carroll, Rami Elghandour, Christopher Heery, Michelle Gilson, Kavita Patel, Olivia C Ware and Olivia C Ware.
View institutional ownership trends.

How do I buy shares of Arcellx?

Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arcellx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcellx investors own include Humana (HUM), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), American Water Works (AWK), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 2/01/2025
• Next Earnings (Estimated): 2/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACLX
• CUSIP: N/A
• CIK: 1786205
• Web: arcellx.com
• Phone: 240-327-0603
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $105.93
• High Stock Price Target: $136.00
• Low Stock Price Target: $73.00
• Potential Upside/Downside: +55.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 15 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-70,690,000.00
• Net Margins: -25.94%
• Pretax Margin: -25.18%
• Return on Equity: -8.28%
• Return on Assets: -5.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.29
• Quick Ratio: 4.29

Sales & Book Value

• Annual Sales: $155.82 million
• Price / Sales: 23.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.97 per share
• Price / Book: 6.83

Miscellaneous

• Outstanding Shares: 54,075,000
• Free Float: 50,701,000
• Market Cap: $3.68 billion
• Optionable: Optionable
• Beta: 0.33